Recursion Pharmaceuticals, Inc. RXRX Finance Lease Liabilities (Total)
Finance Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s finance lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s finance lease liabilities (total)?
- Recursion Pharmaceuticals, Inc. (RXRX) reported finance lease liabilities (total) of $16.2M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s finance lease liabilities (total) changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s finance lease liabilities (total) decreased by 34.1% year-over-year, from $24.6M to $16.2M.
- What does finance lease liabilities (total) mean?
- Finance lease liabilities (total) represent the aggregate present value of all future lease payments for assets where the company assumes substantially all risks and rewards of ownership. This metric reflects the long-term debt-like burden associated with financing infrastructure or equipment through leases. It is a key component of the company's total leverage profile.